by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
GP Week : Issue 234
allowing for the undercut there was a strong chance Hamilton could have taken the lead. In order to not upset the apple cart it changed Hamilton's strategy, extending his second stint and moving him a comfortable distance behind Rosberg as a result. By the time he pitted, with 14 laps left to run, he had a slim chance of victory but for all intents and purposes the race was over. Mercedes had quietly moved Hamilton out of the way, ensuring Rosberg claimed victory. It was subtle, calculated and absoultely the correct decision and while Hamilton did his best tomakearaceofitinthefinal laps his efforts were never likely to bear fruits. Praise must be heaped upon Rosberg for his Abu Dhabi performance. With an older engine, a legacy of his problems in Monza, he had a greater task finding and maintaining the speed to stay ahead. That he did, and didn't make a mistake when his teammate was closing, showed what a confident Nico Rosberg is capable of. On his day, Rosberg is a match for Hamilton, and it is that man the team needs for 2016. During Friday practice there was a suggestion that Ferrari may have mounted a sterner challenge to Mercedes, though that was largely blunted during qualifying. Even still, that Sebastian Vettel was able to race his way back to fourth from 15th on the grid demonstrated how strong the Prancing Horse was in Abu Dhabi, while Kimi Raikkonen put in one of his best performances of the season to secure third place. The problem for Vettel was that, starting so far down the order, by the time he'd cleared traffic he'd already dropped a pit stop behiund his teammate, making any hopes of a podium finish for the German fanciful. Though he perhaps had a better run to the flag in terms of tyres, and he was likely to claw some of that deficit back, the task left before him was simply too great. There were more important signs however as Vettel twice moved aside for Raikkonen, keeping the Fin in the race for a higher place should anything happen to the Mercedes ahead. It hurt his own race, but in reality there was little risk in allowing Raikkonen to pass and it would have only harmed the team's chances had he tried to battle it out. It was a mature, team-centric performance from the former four-time world champion. There was a less composed performance from the man many think will someday be a world champion, as Max Verstappen Jean Boulle Medtech Ltd, a Jean Boulle Group medical technology company and founding investor of Tendyne Holdings, Inc, is pleased to announce that Abbott Laboratories has closed its acquisition of Tendyne. Abbott thereby acquires the remaining shares of Tendyne that it does not already own for US$250 million plus potential future payments tied to regulatory milestones. This acquisition culminates a relationship that began when Jean Boulle Medtech welcomed Abbott as an early strategic investor in Tendyne. Jean Boulle Medtech worked with Tendyne's most recent investor, Apple Tree Partners, in helping to complete the transaction. Tendyne has developed a heart valve specifically designed to address the complex mitral anatomy of functional, degenerative and mixed etiology mitral regurgitation – a disorder in which the mitral valve on the left side of the heart does not close properly. Left untreated, mitral regurgitation can lead to heart failure and death. Many millions of people, in the United States alone, will benefit from mitral valve replacement. The Tendyne mitral valve is literally placed inside a beating heart via a transcatheter and does not require open-heart surgery. There is therefore no need to stop the heart beating, as has been the case up till now. A catheter enters the bottom of the heart through a small tube inserted in a small incision in the patient’s chest. The physician uses the tube to deploy the valve and positions it so that it rests over the heart's existing mitral valve. It is then anchored securely in place by an adjustable tether. The valve is fully retrievable, totally repositionable and is sewn onto a Nitinol frame. Nitinol is a superelastic nickel and titanium "shape memory alloy" whose flexibility eases implantation, but regains its original shape when it returns to a patient’s normal body temperature. The Tendyne valve’s nickel/titanium alloy composition is derived from a corporate history of making major discoveries which Tendyne has in common with three other Jean Boulle Group Companies. The first founded Diamond Fields Resources, Inc, and discovered one of the world's largest and richest nickel deposits in Voisey's Bay, Canada. The second founded Titanium Resources Group Ltd and restarted and rediscovered one the world's largest and richest titanium mines in Sierra Leone. The third, World Titanium Resources discovered and is developing one of the world’s largest and highest- grade titanium deposits, in South Western Madagascar. The Tendyne valve is currently undergoing clinical trials in the United States, Great Britain and Australia as part of a multi- centre global feasibility study on the safety and performance of the Tendyne valve in patients with symptomatic mitral regurgitation of degenerative or functional etiology, some of whose medical conditions would otherwise make them inoperable. Initial patient results have been positive with most, if not all, patients having no mitral valve regurgitation after being discharged from hospital within a few days of surgery. The Tendyne valve has been successfully implanted in patients at such internationally renowned medical institutions as the Royal Brompton Hospital in London, England; St Vincent's Hospital in Sydney, Australia; and The Minneapolis Heart Center at Abbott Northwestern Hospital in Minneapolis, Minnesota. Other prestigious medical institutions in the expanding universe of Tendyne clinical trials include Baylor Heart and Vascular Center, Dallas, Texas; Cleveland Clinic Foundation, Cleveland, Ohio; St. Francis Hospital, Roslyn, New York; and Oslo University Hospital, Oslo, Norway. Members of Tendyne's Medical Advisory team include : Mark Gillinov MD, The Cleveland Clinic Heart Center; Paul Grayburn MD, Baylor Jack and Jane Hamilton Heart and Vascular Hospital; Lucian Lozonschi MD, Associate Professor of Cardiac Surgery, University of Wisconsin School of Medicine and Public Health; Georg Lutter MD, University of Kiel, Eduardo de Marchena MD, Professor of Medicine and Surgery and Associate Dean for International Medicine, University of Miami Health System; Mark Reisman MD, Clinical Professor of Medicine, University of Washington; Murat Tuzcu MD, The Cleveland Clinic; and Horst Sievert MD. Jean Boulle Medtech is a subsidiary of the medical division of the Jean Boulle Group of Companies. This division invests in medical technology and includes companies such as Jean Boulle Medtech (Ocudyne) Ltd., which is the founding investor in a project exploring the cause of, and a cure for, aged-related macular degeneration, a leading cause of blindness around the world. MoRe iNFoRMatioN: Jean Boulle Group Ms Audrey Richardson email@example.com WEB: jeanboullegroup.com or Wayne Malouf, in Dallas, Texas Ph: +1 214 691 9000 firstname.lastname@example.org Jean Boulle Group – Us$250m + Abbott Laboratories Acquisition of Tendyne Holdings 22 GPWEEK.com // 22 GPWEEK.com // F1 >>> ABU DHABI PARTNERS: